Trials / Completed
CompletedNCT00198484
Evaluation of Vitrase as a Spreading Agent
Evaluation of Vitrase (Hyaluronidase for Injection) Ovine, 200 USP Units/mL, as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs Prior to Ocular Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vitrase |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2004-12-01
- Completion
- 2005-02-01
- First posted
- 2005-09-20
- Last updated
- 2013-03-14
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00198484. Inclusion in this directory is not an endorsement.